ZEAL Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 710.50 |
| 52 Week High | DKK 972.00 |
| 52 Week Low | DKK 312.00 |
| Beta | 0.54 |
| 11 Month Change | -12.77% |
| 3 Month Change | -19.72% |
| 1 Year Change | 114.01% |
| 33 Year Change | 398.95% |
| 5 Year Change | 235.77% |
| Change since IPO | 793.71% |
Recent News & Updates
Recent updates
Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher
Nov 09
Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt
Oct 01Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade
Aug 21Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 18Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)
Mar 17Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation
Oct 03Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term
Aug 14Shareholder Returns
| ZEAL | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | -12.9% | -11.8% | -2.1% |
| 1Y | 114.0% | -9.5% | 6.2% |
Return vs Industry: ZEAL exceeded the Danish Biotechs industry which returned -9.5% over the past year.
Return vs Market: ZEAL exceeded the Danish Market which returned 6.2% over the past year.
Price Volatility
| ZEAL volatility | |
|---|---|
| ZEAL Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 10.4% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: ZEAL's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: ZEAL's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 298 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
| ZEAL fundamental statistics | |
|---|---|
| Market cap | DKK 50.19b |
| Earnings (TTM) | -DKK 1.05b |
| Revenue (TTM) | DKK 76.87m |
653.0x
P/S Ratio-47.7x
P/E RatioIs ZEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEAL income statement (TTM) | |
|---|---|
| Revenue | DKK 76.87m |
| Cost of Revenue | DKK 704.13m |
| Gross Profit | -DKK 627.26m |
| Other Expenses | DKK 425.28m |
| Earnings | -DKK 1.05b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 20, 2025
| Earnings per share (EPS) | -14.90 |
| Gross Margin | -816.00% |
| Net Profit Margin | -1,369.25% |
| Debt/Equity Ratio | 3.2% |
How did ZEAL perform over the long term?
See historical performance and comparison